SCHEMBL7250829

SCHEMBL7250829

CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@@H](NC(=O)O)C(C)C)CC2)cc1

nearest known ligand 0.79

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HRH2 P25021 20/20 0.79
HRH1 P35367 20/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7250289 1.00 HRH2 (0.79) HRH2HRH1
SCHEMBL7979799 1.00 HRH2 (0.79) HRH2HRH1
SCHEMBL7251352 0.91 HRH2 (0.80) HRH2HRH1
SCHEMBL7965938 0.90 HRH2 (0.70) HRH2HRH1
SCHEMBL7976421 0.90 HRH2 (0.70) HRH2HRH1
SCHEMBL7251892 0.88 HRH2 (0.80) HRH2HRH1
SCHEMBL7244677 0.88 HRH2 (0.80) HRH2HRH1
SCHEMBL7245974 0.85 HRH2 (1.00) HRH2HRH1
SCHEMBL7246320 0.85 HRH2 (1.00) HRH2HRH1
SCHEMBL7244202 0.84 HRH2 (1.00) HRH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6559140-B2 Cyclic and bicyclic diamino histamine-3 receptor antagonists ABBOTT LABORATORIES 2003-05-06 US claimed
US-20010049367-A1 Cyclic and bicyclic diamino histamine-3 receptor antagonists ABBVIE INC. 2001-12-06 US claimed
US-6559140-B2 Cyclic and bicyclic diamino histamine-3 receptor antagonists ABBOTT LABORATORIES 2003-05-06 US disclosed
US-20010049367-A1 Cyclic and bicyclic diamino histamine-3 receptor antagonists ABBVIE INC. 2001-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049367-A1 Cyclic and bicyclic diamino histamine-3 receptor antagonists HRH4, HRH2, HRH3 HRH2 2/4885HRH1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.